Advertisement

Herz

, Volume 43, Issue 8, pp 746–751 | Cite as

Transcatheter aortic valve replacement with balloon-expandable valve

Analysis of initial experience in China
  • Y. Shen
  • H. Zhang
  • L. Zhang
  • H. Li
  • H. Mao
  • Y. Pei
  • Z. Jing
  • Q. Lu
Open Access
Original articles
  • 360 Downloads

Abstract

Background

Transcatheter aortic valve replacement (TAVR) is widely applied for the treatment of severe aortic stenosis (AS) in developed countries; however, in China, it is still in the early stage of utilization. On the basis of previous studies, this work explored the feasibility of TAVR in patients with severe AS in China and analyzed the cause of death in four cases.

Methods

This retrospective study included 20 patients who had severe AS and underwent TAVR with a balloon-expandable system (Edwards SAPIEN XT) in our hospital from January 2011 to June 2016. The valve and heart functions of 16 survivors before and after the TAVR procedure were compared. TAVR endpoints, device success, and adverse events were assessed according to the definitions of the Valve Academic Research Consortium-2 (VARC-2).

Results

There were 13 male and seven female patients aged 65–81 years (average, 73.15) who underwent TAVR. The TAVR approach was transfemoral in 19 patients and transapical in one patient. Four patients died (two of coronary artery occlusion and two of aortic annulus rupture) during the TAVR procedure or shortly after; six patients had mild paravalvular leakage, and the rest of the patients showed a significant improvement in cardiac function. During the follow-up period (2–62 months), one patient died of lung cancer 13 months after the TAVR procedure.

Conclusion

TAVR with a balloon-expandable system is safe and effective and can be used for patients with severe AS in China. It requires careful patient selection and preoperative assessment so as to reduce the 30-day postoperative mortality rate.

Keywords

Aortic valve stenosis Coronary angiography Minimally invasive surgery Patient selection China 

Transkatheter-Aortenklappenersatz mit ballondilatierbarer Klappe

Auswertung erster Erfahrungen in China

Zusammenfassung

Hintergrund

Der Transkatheter-Aortenklappenersatz („transcatheter aortic valve replacement“, TAVR) ist in Industrieländern zur Behandlung der schweren Aortenstenose (AS) weit verbreitet, in China jedoch ist er immer noch im Frühstadium der Anwendung. Auf der Grundlage vorhergehender Studien wurde in der vorliegenden Arbeit die Durchführbarkeit der TAVR-Operation bei Patienten mit schwerer AS in China untersucht und in 4 Fällen die Todesursache analysiert.

Methoden

In die retrospektive Studie wurden 20 Patienten aufgenommen, bei denen eine schwere AS vorlag und eine TAVR-Operation mit einem ballondilatierbaren System (SAPIEN XT, Fa. Edwards, Irvine/CA, USA) zwischen Januar 2011 und Juni 2016 in der Klinik der Autoren erfolgte. Klappen- und Herzfunktion der 16 überlebenden Patienten wurden vor und nach der TAVR-Operation verglichen. TAVR-Endpunkte, erfolgreicher Geräteeinsatz und Nebenwirkungen wurden gemäß den Definitionen des Valve Academic Research Consortium-2 (VARC-2) ermittelt.

Ergebnisse

Bei 13 männlichen und 7 weiblichen Patienten im Alter von 65 bis 81 Jahren (Durchschnitt: 73,15) wurde eine TAVR-Operation durchgeführt. Der Zugang für den TAVR war bei 19 Patienten transfemoral und bei einem Patienten transapikal. Es starben 4 Patienten (2 durch Koronararterienverschluss und 2 durch eine Ruptur des Aortenrings) während der TAVR-Operation oder kurz danach; 6 Patienten wiesen eine leichtgradige paravalvuläre Leckage auf, und bei den übrigen Patienten zeigte sich eine deutliche Verbesserung der Herzfunktion. Während der Nachbeobachtungsphase (2–62 Monate) starb ein Patient 13 Monate nach der TAVR-Operation an einem Bronchialkarzinom.

Schlussfolgerung

Die TAVR-Operation mit einem ballondilatierbaren System ist sicher und wirksam und kann bei Patienten mit schwerer AS in China eingesetzt werden. Es bedarf einer sorgfältigen Patientenauswahl und präoperativen Untersuchung, um die postoperative 30-Tage-Mortalitätsrate zu senken.

Schlüsselwörter

Aortenklappenstenose Koronarangiographie Minimalinvasive Chirurgie Patientenselektion China 

Aortic stenosis (AS), either congenital or acquired, is a common aortic valve disease among the aged population. Congenital AS is mainly caused by bicuspid aortic valve. Acquired AS is often termed “senile” or “calcific valvular” AS, which is considered a degenerative process. The morbidity rate of AS patients older than 75 years is as high as 2.8% [1]. Although performing surgical aortic valve replacement (SAVR) under extracorporeal circulation is still the most common treatment for AS and can achieve good outcomes, it can also lead to significant patient trauma, inflammatory stress, and other potential risks. This is especially true for the frail older population with severe circulatory, respiratory, or urinary system disease, which greatly increases the surgical risk. Research shows that more than 40% of AS patients older than 75 years cannot tolerate SAVR [1]. At the beginning of this century, transcatheter aortic valve replacement (TAVR) heralded a new era of minimally invasive surgical repair for aortic valve diseases. In 2002, Cribier and colleagues accomplished the first TAVR in humans [2]. Cohort studies [3, 4] also showed that TAVR potentially had a lower procedural mortality than SAVR in all risk groups. TAVR was proved to be an effective and safe treatment and was carried out in developed countries for patients considered high risk for SAVR [5]. However, in developing countries, the technique is relatively new.

From 2011 to 2016, our team made a preliminary attempt to manage patients with valvular heart disease in accordance with the 2014 American Heart Association/American College of Cardiology (AHA/ACC) guideline [6]. During the procedure, transcatheter balloon-dilated aortic valve replacement (Edwards SAPIEN XT) was applied to 20 volunteers who had severe AS and were considered high risk (logistic EuroSCORE >15%) for SAVR [7, 8]. The initial outcomes were encouraging.

Patients and methods

Patients

From January 2011 to June 2016, 20 patients with severe AS were enrolled in this retrospective study. All patients had undergone strict preoperative evaluations using transthoracic echocardiography (TTE), coronary angiography (CAG), computed tomographic angiography (CTA), and lung function tests to assess the cardiac structure and function, systemic vascular conditions, and other comorbidities.

Besides those who refused open surgery, high-risk patients with severe symptomatic AS who were deemed inoperable included those with: (1) severe AS with an aortic valve area of less than 0.8 cm2 plus an aortic velocity no less than 4.0 m/s, or mean pressure gradient equal to or greater than 40 mm Hg with New York Heart Association (NYHA) functional class II or higher; (2) logistic EuroSCORE of 15% or higher. The exclusion criteria were: congenital bicuspid aortic valve, acute myocardial infarction, significant coronary artery disease (CAD), left ventricular ejection fraction (LVEF) <20%, aortic annulus area >650 mm2 or <300 mm2, severe aortic or mitral regurgitation, severe kidney dysfunction, and transient ischemic attack within 6 months [6].

The current study comprised 20 patients (13 male) who had congestive heart failure with NYHA class II–IV and a logistic EuroSCORE higher than 15%. The aortic annulus diameters ranged from 20 to 25 mm, as determined by TTE.

Surgical technique

All operations were performed with the patients under general anesthesia; endotracheal intubation and mechanical ventilation were used during the procedure. Edwards SAPIEN XT Transcatheter Heart Valves (23 mm, 26 mm, and 29 mm) provided by Edwards Lifescience Corp. (Irvine, CA, USA) were used in all patients. Monitoring devices utilized for real-time supervision during the TAVR procedure included transesophageal echocardiography (TEE), three-channel electrocardiogram (ECG), continuous oxygen saturation, and hemodynamic assessment via radial artery catheter. A standard transfemoral retrograde approach was conducted as described by Kasel [9]. All procedures were performed via the transfemoral approach except for one patient with an aortic valve area of 0.22 cm2 in whom the procedure was assisted by the transapical approach.

Statistical analysis

All data are summarized and displayed as mean±SD for continuous variables and numbers (%) for categorical variables. Valve function and heart function before and after TAVR were analyzed and compared by the Wilcoxon signed-rank test or the paired-samples t test (Table 1). All two-tailed test results with a value of p < 0.05 were considered statistically significant.
Table 1

Comparison of valve and heart function before and after TAVR

Characteristics of surviving patients (n = 16)

Before TAVR

After TAVR

p 

LVEF (%)

59.31 ± 11.32

61.88 ± 8.49

0.132

Vmax (cm/s)

512.63 ± 75.71

232.69 ± 71.54

<0.001

NYHA class ≥ II, n (%)

16 (100)

3 (18.75)

<0.001

Values are mean ± SD or n (%)

LVEF left ventricular ejection fraction, NYHA New York Heart Association

Results

A total of 20 patients (13 male) underwent TAVR procedures with the Edwards Sapien XT valve system in our hospital, of which 19 procedures were transfemoral and one was assisted by a transapical approach. The baseline characteristics of patients are presented in Table 2.
Table 2

Baseline patient characteristics

Age (years)

73.15 ± 4.52

Male

13 (65%)

Hypertension

14 (70%)

Diabetes

5 (25%)

CAD

5 (25%)

PAD

1 (5%)

AVA (cm2)

0.74 ± 0.24

EOAI

0.44 ± 0.14

LVEF (%)

58.40 ± 11.46

PGmax (mm Hg)

102.95 ± 32.54

Vmax (cm/s)

503.60 ± 90.06

Left coronary ostial height

13.61 ± 0.80

Right coronary ostial height

14.87 ± 1.22

Logistic EuroSCORE (%)

17.72 ± 3.38

Values are mean ± SD or n (%)

CAD coronary artery disease, PAD peripheral artery disease, AVA aortic valve area, EOAI effective orifice area index, LVEF left ventricular ejection fraction, PGmax maximum pressure gradient, Vmax maximum aortic velocity

Follow-up TTE was performed 1 month, 6 months, and 1 year after the TAVR procedure and annually thereafter. In our study, we mainly focused on the 30-day results. The results are displayed in Table 3 according to the Valve Academic Research Consortium-2 (VARC-2) definitions [10]. Four patients with a mean age of 70.5 years (range 68–72) died during or shortly after the procedure. Of these patients, one was female and two had a history of CAD. All of them had an NYHA class no higher than level III except one patient with level IV. Two patients died of acute myocardial infarction resulting from coronary occlusion, one of them had the left main coronary artery obscured by a native valve during the balloon-expanding procedure, and the other one suffered aortic sinus dissection caused by balloon expansion. Two patients died of pericardial tamponade caused by aortic annulus rupture. Six patients (30%) had mild paravalvular leakage. Neither life-threatening bleeding, vascular complications, operation-correlated cardiac arrhythmia, myocardial infarction, aortic valve displacement, nor severe paravalvular leakage were found. Vital signs were stable in the remaining patients.
Table 3

Outcomes of the 30-day follow-up study

Outcomes

Cases (N = 20)

All-cause mortality (%)

4 (20)

Cardiovascular mortality (%)

4 (20)

Non-cardiovascular mortality (%)

0 (0)

Coronary obstruction (%)

2 (10)

Cardiac tamponade (%)

2 (10)

Bleeding complications (%)

0 (0)

Vascular complications (%)

0 (0)

Conduction disturbances and arrhythmias (%)

0 (0)

Myocardial infarction (%)

0 (0)

Valve migration (%)

0 (0)

Acute kidney injury

0 (0)

Stroke

0 (0)

Paravalvular leakage

Mild (%)

6 (30)

Moderate (%)

0 (0)

Severe (%)

0 (0)

Values are n (%)

TTE showed significant improvement of cardiac function in the 30-day follow-up. The mean maximum aortic velocity decreased from 512.63 ± 75.71 cm/s to 232.69 ± 71.54 cm/s (p < 0.001). Moreover, 13 surviving patients showed an improvement in NYHA functional class to class I within 30 days. During the follow-up period, one patient died of lung cancer after 13 months; the rest of the 15 patients were able to resume their daily activity independently.

Discussion

AS is a significant problem that is directly correlated with advanced age [11]. Because drug therapies have a low efficiency and do not lead to high survival rates, the treatment of severe AS has primarily been SAVR. In the past decade, the emergence of TAVR has offered a less invasive approach for the treatment of patients with severe AS [12]. For these patients, TAVR shows a lower short-term mortality rate compared with SAVR [13], and thus might be a better option. A systematic review [14] showed that TAVR had a mortality rate of 8.4%, among which multiorgan failure accounted for 20.0%, followed by cardiovascular complications and stroke, accounting for 16.0% and 12.0%, respectively. These were the three leading causes of death after TAVR with the Edwards SAPIEN Valve within 30 days according to the review. In our retrospective study, we observed initial success in 16 cases, but there were still four patients who died during the procedure or shortly after. The 30-day mortality rate of the 20 patients in our study was higher than that in the literature (4/20, 20%) [13]; besides the high-risk factors present in the patients themselves (logistic EuroSCORE > 15%), further improvements in the preoperative evaluations and implantation techniques were also required.

Here, we discuss the causes of death in our four patients.

Coronary occlusion

The etiology of coronary occlusion is often multifactorial and generally includes asymmetric expansion caused by bicuspid valve malformation, bulky calcification on the left or right coronary cusps, low take-off of the coronary ostia, large aortic valve leaflets, and shallow aortic sinus.

Aortic sinus dissection as a rare complication caused by TAVR has not been reported in the current literature. However, it can result in myocardial infarction and was considered to be the cause of death of the first patient in our study. The preoperative CTA of the first patient showed an annulus area of 358 mm2 (Fig. 1a); a 23-mm artificial valve with a 17-ml balloon of 1‑ml underfill was chosen, which provided 10.0% oversizing. The take-off of the left coronary artery was 15.4 mm (lower than the right one), and was considered to be a safe distance. After releasing the valve stent, the left coronary ostium was seen to be occluded under digital subtraction angiography (DSA). After percutaneous transluminal coronary angioplasty (PTCA) and stent implantation, the blood flow of the left coronary artery recovered immediately (Fig. 1b). The patient was reported to have acute coronary syndrome (ACS) on the first postoperative day and died afterwards. The take-off of the left coronary ostia was considered safe enough and the CAG showed that the left coronary artery kept patency after stent implantation. As a result, we considered that coronary sinus dissection occurred and led to the acute occlusion of the coronary ostia. The risk factors remained unclear, but could be related to annulus calcification and the balloon-expansion procedure.
Fig. 1

a Aortic annulus area and long- and short-axis diameters. b Coronary angiography after coronary stent implantation

Researchers have shown that [15] a distance of <10 mm between the base of the coronary arteries and the hinge point of the corresponding cusp pose an increased risk for occlusion. Among the 20 patients, the average height of the coronary ostia was 13.64 mm (range, 12.27–15.42 mm) in the left side and 14.87 mm (range, 13.05–16.70 mm) in the right side using the three-dimensional structure software Aquarius Workstation (Version 3.7.0.13, TeraRecon, Foster City, CA, USA). In the second patient, the left coronary ostial height was 15.1 mm (lower than the right) and was considered to be a safe distance (Fig. 2a). Angiography showed that the patency of the cornary arteries were good before stent implantation (Fig. 2b). In other investigations [15], it was pointed out that if the coronary ostial height is shorter than the coronary cusp length, it could also increase the risk of coronary occlusion, which was thought to be the cause of death in the second patient. After releasing the valve stent, the left coronary ostium was covered by a self-leaflet (Fig. 2c). It indicated a shorter left main ostial height (15.1 mm) than the left coronary cusp leaflet length (16.1 mm), which was the main reason for coronary occlusion (Fig. 2a). To avoid such life-threatening situations, surgeons should analyze the preoperative imaging carefully, especially the coronary ostial height, the bulky calcification on the left or right coronary cusps, and the shape of the coronary sinus. For patients with CAD, CAG should be performed before TAVR to decide whether to implant coronary stents or not.
Fig. 2

a Coronary ostial height and coronary cusp length. b Aortic root angiography before TAVR. c Coronary angiography indicating occlusion of the left coronary ostia

After stent implantation, the coronary artery blood supply and the artificial valve stent function should be examined. If there is coronary occlusion, PTCA should be performed immediately. Furthermore, a hybrid operation room should be readily available in the case of coronary artery bypass grafting (CABG).

Aortic annulus rupture

Larger registries [16] reported that periprocedural aortic annular rupture was less than 1% of the total procedures and was more common with balloon-expandable valves. Aortic annulus rupture usually occurs because of poor patient selection, lack of experience, measurement error, aggressive dilatation, valve oversizing (>20% was shown to be associated with an 8.4-fold higher risk of contained and uncontained ruptures with the balloon-expandable system [17]), bulky calcifications in the valve deployment zone (Fig. 3; [17, 18]), severe asymmetric subvalvular hypertrophy, and global left ventricular hypertrophy in the elderly, especially in female patients with relatively weak myocardium.
Fig. 3

Bulky calcification in the valve deployment zone

The third patient who died in our series was a 72-year-old woman with NYHA class IV. Asymmetric hypertrophy of interventricular septum and decreased left ventricular compliance were detected with echocardiography. An aortic annulus area of 500 mm2 with no obvious calcification was found by CTA (Fig. 4). A 26-mm valve with a 22-mm balloon was needed (6.2% oversizing). During the balloon dilatation procedure, there were temporary system errors in the pacemaker, which was observed under DSA and resulted in a slight sliding of the balloon. After balloon displacement, cardiac tamponade occurred. Pericardiocentesis was carried out and the symptoms were gradually controlled. After entering the ICU, however, the patient’s heart rate and blood pressure dropped again within 4 h and she died. Advanced age, female gender, as well as reduced cardiac structure and function were thought to be critical risk factors. The balloon displacement might be the main reason for the aortic annulus rupture.
Fig. 4

Aortic annulus area and long- and short-axis diameters

Extensive calcification of the valve deployment zone is associated with lower device success and increases the risk of rupture during the process of balloon expansion [19]. The fourth patient in our series had an aortic annulus area of 568 mm2 and extensive calcification was found in the valve deployment zone via CTA. A 29-mm valve and a 23-mm balloon with 1‑ml underfill were selected, which had an oversizing of 13.3%. After balloon expansion, hydropericardium was seen under TEE observation. Although pericardiocentesis and exploratory thoracotomy were performed immediately, it still failed to save the patient’s life; the patient died of cardiac tamponade caused by aortic annulus rupture. Whether patients with extensive calcification of the valve deployment zone are suitable for a balloon-expandable valve system and how to select the rate of oversizing are issues that still need further exploration.

Selecting suitable patients and the correct size of the valve system via preoperative imaging assessment is important to reduce the rates of rupture. The rate of oversizing is recommended to be 5–20% when the Sapien XT system is used [17]. In cases of extreme calcification, an average rate of 7.5% is recommended [20] to balance the oversizing that may result in rupture and the undersizing that may result in increased paravalvular regurgitation. Balloon underfilling during valve deployment may also lower the risk of rupture. In addition, it is equally important to ensure the effectiveness and stability of the pacemaker before and during the procedure.

Acute hemodynamic collapse immediately follows the rupture, which can be observed with TEE or DSA. In order to maintain hemodynamic stability, a hybrid operating room is usually required to perform cardiopulmonary bypass and sternotomy with conventional cardiac procedures. Alternatives include isolated pericardial drainage and a conservative strategy if the rupture is contained and the patient is not in an immediate life-threatening situation. Recently, researchers described endovascular repair with the use of tissue glue injection via a microcatheter to seal an annular perforation defect [20]; this requires further validation and long-term follow-up before entering the guidelines.

Limitations

Patient selection and assessment were highly subjective. Family members held different attitudes toward exploratory thoracotomy and autopsy, and some of them rejected the study proposal. Thus, the causes of death in some patients could only be judged by the clinical experiences. The study was a single-center, non-randomly controlled study and had a limited number of patients. It was not adequately powered for clinical or procedural endpoints with the 30-day follow-up period, and therefore further postoperative studies are required.

Conclusion

Although several life-threatening complications occurred and four patients died during TAVR or shortly after, the procedure was successful in the other 16 patients of this study, who had significant improvements in cardiac function during the 30-day follow-up. To avoid complications, better patient selection, more accurate preoperative assessment—especially in aortic root structures—more experienced management, and timely remedial measures are necessary. For single centers with few patients and a lack of treatment experience, multi-institutional programs are needed to further establish a database of endovascular treatment in AS. With accumulation of endovascular experiences and fast-developing techniques, TAVR is expected to be widely applied in developing countries in the near future.

Notes

Compliance with ethical guidelines

Conflict of interest

Y. Shen, H. Zhang, L. Zhang, H. Li, H. Mao, Y. Pei, Z. Jing, and Q. Lu declare that they have no competing interests.

The current study was approved by the Research Ethics Committee of Shanghai Changhai Hospital (CHEC2011-099, 9/16/2011) and a waiver of informed consents was granted as the data was retrospectively reviewed and analyzed anonymously.

References

  1. 1.
    Osnabrugge RL, Mylotte D, Head SJ, Van Mieghem NM, Nkomo VT, LeReun CM, Bogers AJ, Piazza N, Kappetein AP (2013) Aortic stenosis in the elderly:disease prevalence and number of candidates for transcatheter aortic valve replacement:a meta-analysis and modeling study. J Am Coll Cardiol 62(11):1002–1012.  https://doi.org/10.1016/j.jacc.2013.05.015 CrossRefGoogle Scholar
  2. 2.
    Cribier A, Eltchaninoff H, Tron C, Bauer F, Agatiello C, Sebagh L, Bash A, Nusimovici D, Litzler PY, Bessou JP, Leon MB (2004) Early experience with percutaneous transcatheter implantation of heart valve prosthesis for the treatment of end-stage inoperable patients with calcific aortic stenosis. J Am Coll Cardiol 43(4):698–703.  https://doi.org/10.1016/j.jacc.2003.11.026 CrossRefPubMedGoogle Scholar
  3. 3.
    Reardon MJ, Adams DH, Kleiman NS, Yakubov SJ, Coselli JS, Deeb GM, Gleason TG, Lee JS, Hermiller JB Jr, Chetcuti S, Heiser J, Merhi W, Zorn GL 3rd, Tadros P, Robinson N, Petrossian G, Hughes GC, Harrison JK, Maini B, Mumtaz M, Conte JV, Resar JR, Aharonian V, Pfeffer T, Oh JK, Qiao H, Popma JJ (2015) 2‑year outcomes in patients undergoing surgical or self-expanding transcatheter aortic valve replacement. J Am Coll Cardiol 66(2):113–121.  https://doi.org/10.1016/j.jacc.2015.05.017 CrossRefPubMedGoogle Scholar
  4. 4.
    Mohr FW, Holzhey D, Möllmann H, Beckmann A, Veit C, Figulla HR, Cremer J, Kuck KH, Lange R, Zahn R, Sack S, Schuler G, Walther T, Beyersdorf F, Böhm M, Heusch G, Funkat AK, Meinertz T, Neumann T, Papoutsis K, Schneider S, Welz A, Hamm CW (2014) The German Aortic Valve Registry: 1‑year results from 13, 680 patients with aortic valve disease. Eur J Cardiothorac Surg 46(5):808–816.  https://doi.org/10.1093/ejcts/ezu290 CrossRefPubMedGoogle Scholar
  5. 5.
    Jansen F, Werner N (2017) Interventional treatment of the aortic valve:current evidence. Herz.  https://doi.org/10.1007/s00059-017-4585-y CrossRefPubMedGoogle Scholar
  6. 6.
    Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, O’Gara PT, Ruiz CE, Skubas NJ, Sorajja P, Sundt TM 3rd, Thomas JD (2014) 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63(22):2438–2488.  https://doi.org/10.1016/j.jacc.2014.02.537 CrossRefGoogle Scholar
  7. 7.
    Roques F, Nashef SA, Michel P, Gauducheau E, de Vincentiis C, Baudet E, Cortina J, David M, Faichney A, Gabrielle F, Gams E, Harjula A, Jones MT, Pintor PP, Salamon R, Thulin L (1999) Risk factors and outcome in European cardiac surgery: analysis of the Euro-SCORE multinational database of 19030 patients. Eur J Cardiothorac Surg 15(6):816–822.  https://doi.org/10.1016/S1010-7940(99)00106-2 CrossRefPubMedGoogle Scholar
  8. 8.
    Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R (1999) European system for cardiac operative risk evaluation (Euro-SCORE). Eur J Cardiothorac Surg 16(1):9–13.  https://doi.org/10.1016/S1010-7940(99)00134-7 CrossRefPubMedGoogle Scholar
  9. 9.
    Kasel AM, Shivaraju A, Schneider S, Krapf S, Oertel F, Burgdorf C, Ott I, Sumer C, Kastrati A, von Scheidt W, Thilo C (2014) Standardized methodology for transfemoral transcatheter aortic valve replacement with the Edwards Sapien XT valve under fluoroscopy guidance. J Invasive Cardiol 26(9):451–461PubMedGoogle Scholar
  10. 10.
    Kappetein AP, Head SJ, Généreux P, Piazza N, van Mieghem NM, Blackstone EH, Brott TG, Cohen DJ, Cutlip DE, van Es GA, Hahn RT, Kirtane AJ, Krucoff MW, Kodali S, Mack MJ, Mehran R, Rodés-Cabau J, Vranckx P, Webb JG, Windecker S, Serruys PW, Leon MB (2012) Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol 60(15):1438–1454.  https://doi.org/10.1016/j.jacc.2012.09.001 CrossRefGoogle Scholar
  11. 11.
    Dameron MR, Rathore S (2015) Transcatheter aortic valve replacement: When invasive surgery is not an option. J Am Acad Physician Assist 28(2):38–42.  https://doi.org/10.1097/01.JAA.0000459816.02038.b2 CrossRefGoogle Scholar
  12. 12.
    Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Williams M, Dewey T, Kapadia S, Babaliaros V, Thourani VH, Corso P, Pichard AD, Bavaria JE, Herrmann HC, Akin JJ, Anderson WN, Wang D, Pocock SJ (2011) Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 364(23):2187–2198.  https://doi.org/10.1056/NEJMoa1103510 CrossRefGoogle Scholar
  13. 13.
    Ak A, Porokhovnikov I, Kuethe F, Schulze PC, Noutsias M, Schlattmann P (2017) Transcatheter vs. surgical aortic valve replacement and medical treatment: systematic review and meta-analysis of randomized and non-randomized trials. Herz.  https://doi.org/10.1007/s00059-017-4562-5 CrossRefPubMedGoogle Scholar
  14. 14.
    Xiong TY, Liao YB, Zhao ZG, Xu YN, Wei X, Zuo ZL, Li YJ, Cao JY, Tang H, Jilaihawi H, Feng Y, Chen M (2015) Causes of death following transcatheter aortic valve replacement: a systematic review and meta-analysis. J Am Heart Assoc 4(9):e2096.  https://doi.org/10.1161/JAHA.115.002096 CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Smith TW, Bommer WJ (2014) Multimodality imaging in transcatheter aortic valve replacement. Rev Cardiovasc Med 15(2):75–85PubMedGoogle Scholar
  16. 16.
    Pasic M, Unbehaun A, Buz S, Drews T, Hetzer R (2015) Annular rupture during transcatheter aortic valve replacement classification, pathophysiology, diagnostics, treatment approaches, and prevention. JACC Cardiovasc Interv 8(1):1–9.  https://doi.org/10.1016/j.jcin.2014.07.020 CrossRefPubMedGoogle Scholar
  17. 17.
    Barbanti M, Yang TH, Rodès Cabau J, Tamburino C, Wood DA, Jilaihawi H, Blanke P, Makkar RR, Latib A, Colombo A, Tarantini G, Raju R, Binder RK, Nguyen G, Freeman M, Ribeiro HB, Kapadia S, Min J, Feuchtner G, Gurtvich R, Alqoofi F, Pelletier M, Ussia GP, Napodano M, de Brito FS Jr, Kodali S, Norgaard BL, Hansson NC, Pache G, Canovas SJ, Zhang H, Leon MB, Webb JG, Leipsic J (2013) Anatomical and procedural features associated with aortic root rupture during balloon expandable transcatheter aortic valve replacement. Circulation 128(3):244–253.  https://doi.org/10.1161/CIRCULATIONAHA.113.002947 CrossRefPubMedGoogle Scholar
  18. 18.
    Hayashida K, Bouvier E, Lefèvre T, Hovasse T, Morice MC, Chevalier B, Romano M, Garot P, Farge A, Donzeau-Gouge P, Cormier B (2013) Potential mechanism of annulus rupture during transcatheter aortic valve implantation. Catheter Cardiovasc Interv 82(5):E742–E746.  https://doi.org/10.1002/ccd.24524 CrossRefPubMedGoogle Scholar
  19. 19.
    Yigal A, Hasan J, Tarun C, Kashif M, Matar G, Hariri B, Patel J, Nakamura M, Cheng W, Makkar RR (2016) Balloon-expandable transcatheter aortic valve replacement in patients with extreme aortic valve calcification. Catheter Cardiovasc Interv 87(6):1173–1179.  https://doi.org/10.1002/ccd.26311 CrossRefGoogle Scholar
  20. 20.
    Piliero N, Thony F, Vanzetto G, Barone-Rochette G (2015) Gluing of an aortic perforation during transcatheter aortic valve replacement: an alternative treatment for annular rupture? JACC Cardiovasc Interv 8(15):2037–2038.  https://doi.org/10.1016/j.jcin.2015.08.027 CrossRefPubMedGoogle Scholar

Copyright information

© The Author(s) 2017

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  1. 1.Department of Vascular SurgeryChanghai HospitalShanghaiChina

Personalised recommendations